Rivaroxaban + Fondaparinux
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Superficial Vein Thrombosis
Conditions
Superficial Vein Thrombosis
Trial Timeline
Apr 1, 2012 → May 1, 2016
NCT ID
NCT01499953About Rivaroxaban + Fondaparinux
Rivaroxaban + Fondaparinux is a phase 3 stage product being developed by Bayer for Superficial Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01499953. Target conditions include Superficial Vein Thrombosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01499953 | Phase 3 | Completed |
Competing Products
11 competing products in Superficial Vein Thrombosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | enGene | Phase 1/2 | 33 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Diclofenac gel | Novartis | Approved | 85 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Dalteparin sodium injection | Pfizer | Approved | 84 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Chemophase | Halozyme Therapeutics | Phase 1 | 30 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 69 |
| EscharEx 5% (EX-02 formulation) | MediWound | Phase 1/2 | 33 |